http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102032002-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01B25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2012-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102032002-B1 |
| titleOfInvention | Method for preparation of aluminum hydroxyphosphate adjuvant |
| abstract | The present invention relates to a process for preparing amorphous aluminum hydroxyphosphate. The aluminum salt and phosphate solution are co-mixed in a constant ratio in the presence of a buffer. Preferably, excess phosphate solution is used to act as a buffer. Due to the presence of the buffer, the pH remains constant during the reaction (after initial rapid equilibration) without active adjustment. The method is particularly applicable for large scale production of aluminum phosphate adjuvant. Aluminum phosphate is used as an adjuvant in vaccine formulations, particularly vaccine formulations comprising protein or saccharide antigens. |
| priorityDate | 2011-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 121.